Pharma News

Recently, a major scandal has emerged in the pharmaceutical industry as a subsidiary of Johnson & Johnson was ordered by a federal judge to pay $1.64 billion due to illegal marketing practices related to its HIV medications.

Recently, Heng Rui Pharmaceuticals signed an exclusive licensing agreement with Merck for the Lp(a) inhibitor HRS-5346, with a total transaction value reaching $1.97 billion.

In 2024, the oncology drug market continues to hold a pivotal position within the global pharmaceutical industry, achieving record-breaking sales that reflect unprecedented growth potential.

Eli Lilly has announced promising results from a mid-stage trial of its experimental drug, lepodisiran, which significantly lowers levels of lipoprotein(a), or Lp(a), a genetic risk factor for heart disease.

A recent study published in JAMA Ophthalmology has revealed alarming findings regarding Ozempic, a popular diabetes medication.

On March 28, Lexicon Pharmaceuticals announced a significant exclusive licensing agreement with Novo Nordisk for the development of LX9851, the first oral non-incretin-based candidate drug aimed at treating obesity and related metabolic disorders.

On March 26, 2025, Merck and Roche Pharmaceuticals officially announced a strategic partnership aimed at accelerating the commercialization of Tepotinib (brand name: Togetican®) in the mainland Chinese market. I

Eisai has significantly revised its sales expectations for lecanemab, the Alzheimer's treatment developed in collaboration with Biogen, cutting its forecast for the fiscal year 2027 by as much as 50%.

Merck announced a significant investment of nearly $2 billion to acquire rights to HRS-5346, a novel oral small molecule inhibitor targeting lipoprotein(a) [Lp(a)], developed by Hengrui Medicine.

U.S. healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest more than $55 billion in the United States over the next four years. The company said the massive investment is a 25% increase over the previous four years.

• Johnson & Johnson

AstraZeneca, a British company, hopes to invest $2.5 billion to establish its sixth global strategic R&D center in Beijing.

• AstraZeneca
• Beijing
• R&D Center

Eli Lilly officially launched Mounjaro (tirzepatide) in India, following marketing authorization from the Central Drugs Standard Control Organisation (CDSCO).

Piramal Critical Care, part of Piramal Pharma, along with BrePco Biopharma from Ireland, announced that they have received marketing approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Neoatricon.

Swiss pharmaceutical giant Roche has announced the abandonment of its global diversity targets due to concerns over recent U.S. executive orders.

Pfizer announced its decision to sell its entire stake in Haleon, the British consumer healthcare company formed from the merger of GSK and Pfizer's consumer healthcare sectors in 2019.

The pharmaceutical industry is on high alert as the ongoing US-EU tariff spat could potentially target best-selling drugs, raising concerns about increased prices and reduced patient access.

Pfizer China announced significant leadership changes and organizational adjustments within its oncology division.

National Medical Products Administration (NMPA) of China announced the suspension of imports from KYOWA HAKKO BIO CO., LTD. due to non-compliance with approved production protocols at its Hofu factory.

Bayer's 2024 financial report reads like a meticulously crafted thriller, presenting a surface revenue of €46.6 billion that belies the underlying turmoil.

AstraZeneca announced significant findings from the first human clinical trial of its ADC drug, puxitatug samrotecan (P-Sam), targeting B7-H4 in patients with endometrial cancer.